TVTX Quote, Financials, Valuation and Earnings

Edwards Lifesciences Corp. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of 18.82%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Edwards Lifesciences Corp.'s return on equity of 13.19%.

Travere Therapeutics, Inc. has a consensus price target of $41.6429, signalling upside risk potential of 17.77%. On the other hand Edwards Lifesciences Corp. has an analysts' consensus of $95.80 which suggests that it could grow by 11.02%. Given that Travere Therapeutics, Inc. has higher upside potential than Edwards Lifesciences Corp., analysts believe Travere Therapeutics, Inc. is more attractive than Edwards Lifesciences Corp..

Travere Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Edwards Lifesciences Corp. has a beta of 0.968, suggesting its less volatile than the S&P 500 by 3.229%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edwards Lifesciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Edwards Lifesciences Corp. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are smaller than Edwards Lifesciences Corp. quarterly revenues of $1.6B. Travere Therapeutics, Inc.'s net income of $25.7M is lower than Edwards Lifesciences Corp.'s net income of $292.3M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Edwards Lifesciences Corp.'s PE ratio is 36.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 7.36x versus 8.62x for Edwards Lifesciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

iRhythm Technologies, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of -2.7%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat iRhythm Technologies, Inc.'s return on equity of -54.18%.

Travere Therapeutics, Inc. has a consensus price target of $41.6429, signalling upside risk potential of 17.77%. On the other hand iRhythm Technologies, Inc. has an analysts' consensus of $218.60 which suggests that it could grow by 24.35%. Given that iRhythm Technologies, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe iRhythm Technologies, Inc. is more attractive than Travere Therapeutics, Inc..

Travere Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison iRhythm Technologies, Inc. has a beta of 1.099, suggesting its more volatile than the S&P 500 by 9.93%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iRhythm Technologies, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. iRhythm Technologies, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are smaller than iRhythm Technologies, Inc. quarterly revenues of $192.9M. Travere Therapeutics, Inc.'s net income of $25.7M is higher than iRhythm Technologies, Inc.'s net income of -$5.2M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while iRhythm Technologies, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 7.36x versus 7.95x for iRhythm Technologies, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of 28.31%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Travere Therapeutics, Inc. has a consensus price target of $41.6429, signalling upside risk potential of 17.77%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $599.60 which suggests that it could grow by 3.89%. Given that Travere Therapeutics, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Intuitive Surgical, Inc..

Travere Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.682, suggesting its more volatile than the S&P 500 by 68.249%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Travere Therapeutics, Inc.'s net income of $25.7M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 76.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 7.36x versus 21.83x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of 14.18%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Stryker Corp.'s return on equity of 14.06%.

Travere Therapeutics, Inc. has a consensus price target of $41.6429, signalling upside risk potential of 17.77%. On the other hand Stryker Corp. has an analysts' consensus of $428.11 which suggests that it could grow by 20.66%. Given that Stryker Corp. has higher upside potential than Travere Therapeutics, Inc., analysts believe Stryker Corp. is more attractive than Travere Therapeutics, Inc..

Travere Therapeutics, Inc. has a beta of 0.886, which suggesting that the stock is 11.435% less volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.95% to investors and pays a quarterly dividend of $0.84 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Travere Therapeutics, Inc.'s net income of $25.7M is lower than Stryker Corp.'s net income of $859M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Stryker Corp.'s PE ratio is 46.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 7.36x versus 5.62x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.